Development of a Scalable Manufacturing Process for Alectinib with a Concise Preparation of the Indole-Containing Tetracyclic Core

已完结 10 由大欣发布于 2025/3/11 9:30:05

DOI:10.1021/acs.oprd.4c00376
作者：Tomohiro Oki, Masao Tsukazaki, Junichi Shiina, Hiroshi Fukuda, Minoru Yamawaki, Yasushi Kito, Takenori Ishizawa, Kazutomo Kinoshita, Sosuke Hara, Noriyuki Furuichi, Hatsuo Kawada, Toshiya Ito, Kota Ta
文献类型：期刊论文
补充材料：只需要正文

American Chemical Society (ACS)

Abstract：Alectinib (marketed as Alecensa) is an oral, highly potent ALK inhibitor for the treatment of ALK-positive, non–small-cell lung cancer (NSCLC). This paper describes the evolution from a medi

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:NatureClinical translation of silica nanoparticles